Strategic Partnerships Target biotech and ophthalmology alliances with gene-agnostic platforms and retinal disease expertise to co-develop or license SPVN06/SPVN20 programs, leveraging SparingVision’s precedent in advancing platform-in-a-product gene therapies.

Clinical Expansion Position SparingVision for collaboration around pivotal studies planned for 2027 by offering strategic advisory, co-funding, or joint trial execution support with contract research organizations and ophthalmology centers to accelerate timing and de-risk programs.

Funding Levers Leverage disclosed €60M funding and ongoing investor credibility to attract non-dilutive grants or milestone-based partnerships from philanthropic and public funding bodies focused on vision restoration and rare retinal diseases.

Market Readiness Highlight the broad applicability of gene-agnostic approaches to multiple retinal diseases beyond RP to engage pharma companies seeking scalable platform technologies and diversify potential commercialization pathways.

Key Leadership Engage newly appointed Chief Medical Officer and leadership momentum to position clinical milestones as business development anchors for strategic collaborations, licensing discussions, and joint development opportunities.